SNYR|EPS -$1.35 vs $0.01 est |Rev $6.1M|Net Loss $14.8MSynergy CHC Corp. posted a net loss of $14.8M for Q4 2025, translating to a loss per share of $1.35 compared to the consensus estimate of $0.01 earnings. The healthcare company’s quarterly results marked a sharp reversal from Q4 2024, when it recorded EPS of $0.01.
Revenue totaled $6.1M for the quarter, down 40.8% from the $10.3M recorded in Q4 2024. The steep decline in both top and bottom line metrics signals significant headwinds for the company during the final three months of the year. Loss per share widened dramatically, down 13400.0% from the prior-year period.
Despite the challenging quarter, Wall Street maintains a relatively optimistic stance on Synergy CHC Corp., with analyst consensus standing at 5 buy, 1 hold, and 0 sell ratings. The quarter’s results represent a substantial setback for the company as it navigates operational challenges in the healthcare sector.
A detailed analysis of Synergy CHC Corp.’s quarter follows shortly on AlphaStreet.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.
The post Synergy CHC Corp. (SNYR) Misses Q4 EPS Estimates first appeared on Alphastreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
